e-Edition
Obituaries
Photo Gallery
Magazines
News Crew
Paywall Login
Login to Comment
Register
December 15th, 2015
Menu
Home
News
Sports
Business
Entertainment
Federal Election
Classifieds
Life
Commentary
Contact
Local News
Provincial News
National News
World News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vor Biopharma Inc
(NQ:
VOR
)
0.7446
+0.0178 (+2.45%)
Streaming Delayed Price
Updated: 12:14 PM EDT, Oct 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vor Biopharma Inc
< Previous
1
2
Next >
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
September 30, 2024
From
Vor Biopharma
Via
GlobeNewswire
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
September 05, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
August 28, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
August 08, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 09, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
May 09, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
May 06, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors
May 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
April 01, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
March 04, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
January 17, 2024
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 21, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit
November 27, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference
November 09, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
November 07, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
November 03, 2023
From
Vor Biopharma
Via
GlobeNewswire
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform
November 02, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
September 25, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
August 30, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
August 10, 2023
From
Vor Biopharma
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Twitter
Facebook
YouTube
Tumblr